11.07.2021, 1011 Zeichen

Valneva: Valneva SE, an Austrian/French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration (FDA). Breakthrough Therapy Designation intends to facilitate and expedite development and review of new drugs for serious or life-threatening conditions where preliminary clinical data demonstrates that the drug may have substantial improvement for at least one endpoint over available therapies. This new U.S. milestone comes in addition to the FDA Fast Track designation and the European Medicines Agency (EMA)’s PRIME designation which the Company received in December 2018 and in October 2020, respectively.
Valneva: weekly performance: -1.12%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/07/2021)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1208: ATX etwas leichter, ETF-Rebalancing bei AT&S, Telekom Austria gesucht und ein Spoiler zu boerse@home

Bildnachweis

Aktien auf dem Radar:Kapsch TrafficCom, Lenzing, Palfinger, Austriacard Holdings AG, Amag, Semperit, Rosgix, voestalpine, CA Immo, Telekom Austria, Porr, AT&S, ATX, ATX TR, ATX NTR, Verbund, SBO, OMV, Heid AG, RBI, Wolford, BTV AG, DO&CO, EuroTeleSites AG, CPI Europe AG, Österreichische Post, UBM.

---